Amniotic fluid stem cell administration can prevent epithelial injury from necrotizing enterocolitis.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
05
02
2021
accepted:
21
06
2021
revised:
11
05
2021
pubmed:
26
9
2021
medline:
29
3
2022
entrez:
25
9
2021
Statut:
ppublish
Résumé
Stem cell therapy has been proven to rescue intestinal injury and stimulate intestinal regeneration in necrotizing enterocolitis (NEC). Specifically, stem cells derived from amniotic fluid (AFSCs) and mesenchymal stem cells (MSCs) derived from bone marrow have shown promising results in the treatment of experimental NEC. This study aims to examine the effects of AFSCs and MSCs on the prevention of intestinal injury during experimental NEC. Supernatants from AFSC and MSC cultures were collected to perform proteomic analysis. Prior to NEC induction, mice received intraperitoneal injections of phosphate-buffered saline (PBS), 2 × 10 We found that AFSCs grew faster than MSCs. Proteomic analysis indicated that AFSCs are primarily involved in cell development and growth, while MSCs are involved in immune regulation. Administering AFSCs before NEC induction decreased NEC severity and mucosal inflammation. Intestinal proliferation and endogenous stem cell activation were increased after AFSC administration. However, administering MSCs before NEC induction had no beneficial effects. This study demonstrated that AFSCs and MSCs have different protein release profiles. AFSCs can potentially be used as a preventative strategy for neonates at risk of NEC, while MSCs cannot be used. AFSCs and MSCs have distinct protein secretory profiles, and AFSCs are primarily involved in cell development and growth, while MSCs are involved in immune regulation. AFSCs are unique in transiently enhancing healthy intestinal epithelial cell growth, which offers protection against the development of experimental NEC. The prevention of NEC via the administration of AFSCs should be evaluated in infants at great risk of developing NEC or in infants with early signs of NEC.
Sections du résumé
BACKGROUND
Stem cell therapy has been proven to rescue intestinal injury and stimulate intestinal regeneration in necrotizing enterocolitis (NEC). Specifically, stem cells derived from amniotic fluid (AFSCs) and mesenchymal stem cells (MSCs) derived from bone marrow have shown promising results in the treatment of experimental NEC. This study aims to examine the effects of AFSCs and MSCs on the prevention of intestinal injury during experimental NEC.
METHODS
Supernatants from AFSC and MSC cultures were collected to perform proteomic analysis. Prior to NEC induction, mice received intraperitoneal injections of phosphate-buffered saline (PBS), 2 × 10
RESULTS
We found that AFSCs grew faster than MSCs. Proteomic analysis indicated that AFSCs are primarily involved in cell development and growth, while MSCs are involved in immune regulation. Administering AFSCs before NEC induction decreased NEC severity and mucosal inflammation. Intestinal proliferation and endogenous stem cell activation were increased after AFSC administration. However, administering MSCs before NEC induction had no beneficial effects.
CONCLUSIONS
This study demonstrated that AFSCs and MSCs have different protein release profiles. AFSCs can potentially be used as a preventative strategy for neonates at risk of NEC, while MSCs cannot be used.
IMPACT
AFSCs and MSCs have distinct protein secretory profiles, and AFSCs are primarily involved in cell development and growth, while MSCs are involved in immune regulation. AFSCs are unique in transiently enhancing healthy intestinal epithelial cell growth, which offers protection against the development of experimental NEC. The prevention of NEC via the administration of AFSCs should be evaluated in infants at great risk of developing NEC or in infants with early signs of NEC.
Identifiants
pubmed: 34561550
doi: 10.1038/s41390-021-01657-6
pii: 10.1038/s41390-021-01657-6
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-106Subventions
Organisme : CIHR
ID : PJT-169060
Pays : Canada
Informations de copyright
© 2021. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Références
Neu, J. & Walker, W. A. Necrotizing enterocolitis. N. Engl. J. Med. 364, 255–264 (2011).
pubmed: 21247316
pmcid: 3628622
doi: 10.1056/NEJMra1005408
Yee, W. H. et al. Incidence and timing of presentation of necrotizing enterocolitis in preterm infants. Pediatrics 129, e298–e304 (2012).
pubmed: 22271701
doi: 10.1542/peds.2011-2022
Pierro, A. The surgical management of necrotising enterocolitis. Early Hum. Dev. 81, 79–85 (2005).
pubmed: 15707718
doi: 10.1016/j.earlhumdev.2004.10.018
Thyoka, M. et al. Advanced necrotizing enterocolitis part 1: mortality. Eur. J. Pediatr. Surg. 22, 8–12 (2012).
pubmed: 22434227
doi: 10.1055/s-0032-1306263
Tayman, C. et al. Mesenchymal stem cell therapy in necrotizing enterocolitis: a rat study. Pediatr. Res. 70, 489–494 (2011).
pubmed: 21772224
doi: 10.1203/PDR.0b013e31822d7ef2
Yang, J. et al. Heparin-binding epidermal growth factor-like growth factor and mesenchymal stem cells act synergistically to prevent experimental necrotizing enterocolitis. J. Am. Coll. Surg. 215, 534–545 (2012).
pubmed: 22819639
pmcid: 3444529
doi: 10.1016/j.jamcollsurg.2012.05.037
Wei, J., Zhou, Y. & Besner, G. E. Heparin-binding EGF-like growth factor and enteric neural stem cell transplantation in the prevention of experimental necrotizing enterocolitis in mice. Pediatr. Res. 78, 29–37 (2015).
pubmed: 25806717
pmcid: 4472527
doi: 10.1038/pr.2015.63
Zani, A. et al. Amniotic fluid stem cells prevent development of ascites in a neonatal rat model of necrotizing enterocolitis. Eur. J. Pediatr. Surg. 24, 57–60 (2014).
pubmed: 23852724
doi: 10.1055/s-0033-1350059
Zani, A. et al. Amniotic fluid stem cells improve survival and enhance repair of damaged intestine in necrotising enterocolitis via a COX-2 dependent mechanism. Gut 63, 300–309 (2014).
pubmed: 23525603
doi: 10.1136/gutjnl-2012-303735
De Coppi, P. et al. Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. 25, 100–106 (2007).
pubmed: 17206138
doi: 10.1038/nbt1274
Arnhold, S. et al. Amniotic-fluid stem cells: growth dynamics and differentiation potential after a CD-117-based selection procedure. Stem Cells Int. 2011, 715341 (2011).
pubmed: 21437196
pmcid: 3062157
doi: 10.4061/2011/715341
Li, B. et al. Activation of Wnt signaling by amniotic fluid stem cell-derived extracellular vesicles attenuates intestinal injury in experimental necrotizing enterocolitis. Cell Death Dis. 11, 750 (2020).
pubmed: 32929076
pmcid: 7490270
doi: 10.1038/s41419-020-02964-2
Koike, Y. et al. Remote ischemic conditioning counteracts the intestinal damage of necrotizing enterocolitis by improving intestinal microcirculation. Nat. Commun. 11, 4950 (2020).
pubmed: 33009377
pmcid: 7532542
doi: 10.1038/s41467-020-18750-9
Walsh, M. C. & Kliegman, R. M. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr. Clin. N. Am. 33, 179–201 (1986).
doi: 10.1016/S0031-3955(16)34975-6
Bell, M. J. et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann. Surg. 187, 1–7 (1978).
pubmed: 413500
pmcid: 1396409
doi: 10.1097/00000658-197801000-00001
McCulloh, C. J. et al. Evaluating the efficacy of different types of stem cells in preserving gut barrier function in necrotizing enterocolitis. J. Surg. Res. 214, 278–285 (2017).
pubmed: 28624056
pmcid: 5474934
doi: 10.1016/j.jss.2017.03.026
Antounians, L. et al. The regenerative potential of amniotic fluid stem cell extracellular vesicles: lessons learned by comparing different isolation techniques. Sci. Rep. 9, 1837 (2019).
pubmed: 30755672
pmcid: 6372651
doi: 10.1038/s41598-018-38320-w
Zani, A. et al. A spectrum of intestinal injury models in neonatal mice. Pediatr. Surg. Int. 32, 65–70 (2016).
pubmed: 26552653
doi: 10.1007/s00383-015-3813-x
Dvorak, B. et al. Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model. Am. J. Physiol. Gastrointest. Liver Physiol. 282, G156–G164 (2002).
pubmed: 11751169
doi: 10.1152/ajpgi.00196.2001
Ran-Ressler, R. R. et al. Branched chain fatty acids reduce the incidence of necrotizing enterocolitis and alter gastrointestinal microbial ecology in a neonatal rat model. PLoS ONE 6, e29032 (2011).
pubmed: 22194981
pmcid: 3237582
doi: 10.1371/journal.pone.0029032
Li, B. et al. Impaired Wnt/beta-catenin pathway leads to dysfunction of intestinal regeneration during necrotizing enterocolitis. Cell Death Dis. 10, 743 (2019).
pubmed: 31582728
pmcid: 6776513
doi: 10.1038/s41419-019-1987-1
Li, B. et al. Inhibition of corticotropin-releasing hormone receptor 1 and activation of receptor 2 protect against colonic injury and promote epithelium repair. Sci. Rep. 7, 46616 (2017).
pubmed: 28492284
pmcid: 5425914
doi: 10.1038/srep46616
Pozzobon, M., Piccoli, M., Schiavo, A. A., Atala, A. & De Coppi, P. Isolation of c-Kit+ human amniotic fluid stem cells from second trimester. Methods Mol. Biol. 1035, 191–198 (2013).
pubmed: 23959992
doi: 10.1007/978-1-62703-508-8_16
Schiavo, A. A. et al. Endothelial properties of third-trimester amniotic fluid stem cells cultured in hypoxia. Stem Cell Res. Ther. 6, 209 (2015).
pubmed: 26519360
pmcid: 4628318
doi: 10.1186/s13287-015-0204-0
Koike, Y. et al. The intestinal injury caused by ischemia-reperfusion is attenuated by amniotic fluid stem cells via the release of tumor necrosis factor-stimulated gene 6 protein. FASEB J. 34, 6824–6836 (2020).
pubmed: 32223023
doi: 10.1096/fj.201902892RR
Ceulemans, H. & Bollen, M. Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiological Rev. 84, 1–39 (2004).
doi: 10.1152/physrev.00013.2003
Firth, S. M. & Baxter, R. C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23, 824–854 (2002).
pubmed: 12466191
doi: 10.1210/er.2001-0033
Ferry, R. J. Jr., Katz, L. E., Grimberg, A., Cohen, P. & Weinzimer, S. A. Cellular actions of insulin-like growth factor binding proteins. Horm. Metab. Res. 31, 192–202 (1999).
pubmed: 10226802
pmcid: 4151550
doi: 10.1055/s-2007-978719
Grimberg, A. & Cohen, P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J. Cell. Physiol. 183, 1–9 (2000).
pubmed: 10699960
pmcid: 4144680
doi: 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J
Jogie-Brahim, S., Feldman, D. & Oh, Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr. Rev. 30, 417–437 (2009).
pubmed: 19477944
pmcid: 2819737
doi: 10.1210/er.2008-0028
Granata, R. et al. Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J. 18, 1456–1458 (2004).
pubmed: 15247143
doi: 10.1096/fj.04-1618fje
Chang, K. H. et al. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc. Natl Acad. Sci. USA 104, 10595–10600 (2007).
pubmed: 17567755
pmcid: 1965558
doi: 10.1073/pnas.0702072104
Takaoka, M. et al. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res. 64, 7711–7723 (2004).
pubmed: 15520175
pmcid: 4140096
doi: 10.1158/0008-5472.CAN-04-0715
Good, M. et al. Breast milk protects against the development of necrotizing enterocolitis through inhibition of Toll-like receptor 4 in the intestinal epithelium via activation of the epidermal growth factor receptor. Mucosal Immunol. 8, 1166–1179 (2015).
pubmed: 25899687
pmcid: 4540669
doi: 10.1038/mi.2015.30
Nousbeck, J. et al. Insulin-like growth factor-binding protein 7 regulates keratinocyte proliferation, differentiation and apoptosis. J. Investig. Dermatol. 130, 378–387 (2010).
pubmed: 19710688
doi: 10.1038/jid.2009.265
Skardal, A. et al. Bioprinted amniotic fluid-derived stem cells accelerate healing of large skin wounds. Stem Cells Transl. Med. 1, 792–802 (2012).
pubmed: 23197691
pmcid: 3659666
doi: 10.5966/sctm.2012-0088
Sato, Y. et al. Prophylactic therapy with human amniotic fluid stem cells improved survival in a rat model of lipopolysaccharide-induced neonatal sepsis through immunomodulation via aggregates with peritoneal macrophages. Stem Cell Res. Ther. 11, 300 (2020).
pubmed: 32690106
pmcid: 7370504
doi: 10.1186/s13287-020-01809-1
Thomas, H. Intestinal homeostasis is reliant on self-maintaining macrophages. Nat. Rev. Gastroenterol. Hepatol. 15, 656–657 (2018).
pubmed: 30315310
doi: 10.1038/s41575-018-0074-x
McCulloh, C. J., Olson, J. K., Zhou, Y., Wang, Y. & Besner, G. E. Stem cells and necrotizing enterocolitis: a direct comparison of the efficacy of multiple types of stem cells. J. Pediatr. Surg. 52, 999–1005 (2017).
pubmed: 28366560
pmcid: 5467690
doi: 10.1016/j.jpedsurg.2017.03.028
Dvorakova, J., Hruba, A., Velebny, V. & Kubala, L. Isolation and characterization of mesenchymal stem cell population entrapped in bone marrow collection sets. Cell Biol. Int. 32, 1116–1125 (2008).
pubmed: 18562221
doi: 10.1016/j.cellbi.2008.04.024
Zhu, H. et al. A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone. Nat. Protoc. 5, 550–560 (2010).
pubmed: 20203670
doi: 10.1038/nprot.2009.238